Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPG1094 in advanced solid tumors
NCT06212076Phase 2Recruiting
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IPG1094 in solid tumor, sponsored by Nanjing Immunophage Biotech Co., Ltd.. Started Jul 2024; status: recruiting.
02
Drugs
IPG1094
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06212076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212076.